ACHV250117P7500
- 0.00
- 0.000.00%
Achieve Life Newsroom
Express News | Achieve Life Sciences Appoints DR. Kristen Slaoui and Nancy Phelan to Its Board of Directors
Press Release: Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to Its Board of Directors
Oppenheimer Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)
Achieve Life Sciences Reaches Milestone in Clinical Trial for Smoking Cessation Drug
JonesTrading Maintains Achieve Life(ACHV.US) With Buy Rating, Maintains Target Price $20
Achieve Life Sciences (ACHV) Gets a Buy From JonesTrading
Express News | Achieve Life Sciences Inc - on Track for Nda Submission in Q2 2025
Express News | Achieve Life Sciences Inc - No Safety Concerns Identified in Orca-Ol Trial
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Express News | Achieve Life Sciences Announces Critical Milestone Successfully Reached in Orca-Ol Cytisinicline Clinical Trial Required for Nda Submission
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1?
Institutional Shareholders May Be Less Affected by Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Pullback Last Week After a Year of 0.5% Returns
Express News | Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer
Press Release: Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer
Lake Street Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)
Achieve Life To Advance Cytisinicline Into Phase 3 Study For Vaping Cessation In Q3, 2025
Achieve Life Sciences Announces Outcome of End-of-Phase 2 Meeting With FDA
Express News | Achieve Life Sciences Inc - Expects to File Nda for Smoking Cessation in Q2 2025
Express News | Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting With FDA